Disease modifying therapies withdrawal in inactive Secondary Progressi
Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years
What was tested
Compared with
- Interferon beta-1a
Interferon alpha/beta receptor agonist
- Interferon beta-1b
Interferon alpha/beta receptor agonist
- PLEDIGRY
- Glatiramer acetate
Unknown
- Teriflunomide
Dihydroorotate dehydrogenase inhibitor
- Dimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
- Fingolimod
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
- IMUREL
- NOVATREX
- Mycophenolate mofetil
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Cyclophosphamide anhydrous
What it measured
Main measures
Percentage of patients experiencing disability progression (confirmed at 6 months) at 2 years.
Disability progression
Other measures (1)
Disability
Loading reviews and guidelines…
History
- In scope changed from true to false
Started
Jun 2018
Assembled by software from public sources.